Clinical trial · Observational
IL-8+ naïve T Cells as a Biomarker for Thymoma Identification
IL-8+ naïve T Cells as a Biomarker for Thymoma Identification: A Prospective, Multi-center Diagnostic Accuracy Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
According to the existing literature reports, the misdiagnosis rate of CT is as high as 22% - 68%. Thymic cyst and lymphoma are usually misdiagnosed as thymoma, resulting in many unnecessary operations; In addition, traditional imaging technologies can also cause a missed diagnosis rate of about 7%, which is common in the missed diagnosis of asymptomatic thymoma, which delays the opportunity of treatment. Therefore, in order to accurately treat thymic tumors, the existing diagnostic methods of thymic tumors need to be further optimized. Our previous retrospective study found that the level of IL-8 + initial T cells can well distinguish thymoma from other types of anterior mediastinal tumors, and the sensitivity and specificity are close to 95%.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Thymoma | Thymoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| level of IL-8+ initial T cells | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- The sensitivity of levels of IL-8+ initial T cells in the diagnosis of thymoma
- timeFrame
- Through study completion, an average of 2 year
- measure
- The specificity of levels of IL-8+ initial T cells in the diagnosis of thymoma
- timeFrame
- Through study completion, an average of 2 year
- measure
- The cutoff value of levels of IL-8+ initial T cells in the diagnosis of thymoma
- timeFrame
- Through study completion, an average of 2 year
Secondary outcomes (9)
- measure
- The sensitivity of levels of PLXND1+ initial T cells in the diagnosis of thymoma
- timeFrame
- Through study completion, an average of 2 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult, aged 18 and above； * Patients with anterior mediastinal mass on imaging (chest CT or MRI)； * The patient's anterior mediastinal mass can be diagnosed by biopsy or surgery. Exclusion Criteria: * Adolescents and children under the age of 18; * The patient's anterior mediastinal mass can not be diagnosed by biopsy or surgery.
References
Publications (0)
Data not yet available